Psychiatry Research最新文献

{"title":"Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts","authors":"Jose de Leon ,&nbsp;Marina Sagud ,&nbsp;Emilio J. Sanz ,&nbsp;Carlos De las Cuevas","doi":"10.1016/j.psychres.2025.116408","DOIUrl":"10.1016/j.psychres.2025.116408","url":null,"abstract":"<div><div>Croatia has implemented anti-suicide measures due to its high suicide rates. Clozapine has anti-suicidal effects. Using the international database (VigiBase), we explored Croatia's unusual clozapine pharmacovigilance. First, we compared the United Kingdom (UK) with Croatia for clozapine adverse drug reactions (ADRs) and fatal outcomes from clozapine's introduction through January 15, 2023. If the UK is considered 1, and after adjusting for population, Croatia had much lower rates (1 vs. 0.08 for clozapine ADR reports, 1 vs. 0.02 for fatal outcomes and 1 vs. 0.14 for percentage of clozapine reports out of all drug reports). Through 2023, the UK had 52,252 ADR reports and 6,567 fatal outcomes from clozapine-treated patients vs. Croatia with 395 reports and 6 fatal outcomes. The Croatian pharmacovigilance agency (and most national agencies) needs to learn from the UK's agency to better report clozapine ADRs. Second, we analyze suicide behaviors in Croatian clozapine-treated patients reported to VigiBase. Through 2023 the UK reported 537 clozapine-treated patients with at least 1 suicidal behavior versus 95 from Croatia. After adjusting for population, the UK reported a much smaller number of reports of suicidal behavior than Croatia (1 vs. 2.73). This overreporting by Croatian physicians may be a sign of the success of Croatia's anti-suicide measures. The percentage of fatal outcomes in 77 Croatian patients with an intentional overdose was 1.3 % (1/77) vs. 16.8 % in 411 non-Croatian patients, but this is possibly contaminated by early reporting (patients might die after the report). Longitudinal studies of clozapine overdoses in Croatia are needed.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"347 ","pages":"Article 116408"},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics","authors":"Stefano Damiani ,&nbsp;Aldo D'Imperio ,&nbsp;Joaquim Radua ,&nbsp;Lydia Fortea ,&nbsp;Matteo Calò ,&nbsp;Andrea Crippa ,&nbsp;Cecilia Maria Esposito ,&nbsp;Estella Linda Luisa Lumer ,&nbsp;Sara Patron ,&nbsp;Alessandro Peviani ,&nbsp;Alessandro Piccolo ,&nbsp;Umberto Provenzani ,&nbsp;Fabrizio Santilli ,&nbsp;Cecilia Spallarossa ,&nbsp;Laura Fusar-Poli ,&nbsp;Evangelos Papanastasiou ,&nbsp;Matteo Cella ,&nbsp;Rashmi Patel ,&nbsp;Silvana Galderisi ,&nbsp;Stefan Leucht ,&nbsp;Paolo Fusar-Poli","doi":"10.1016/j.psychres.2025.116406","DOIUrl":"10.1016/j.psychres.2025.116406","url":null,"abstract":"<div><div>Negative symptoms in schizophrenia spectrum are associated with minimal treatment responses. The search for effective treatments is potentially hampered by heterogenous study-designs and sample characteristics depending on the intervention category. This PRISMA-compliant systematic review/synthesis aims to describe the literature on negative symptoms interventions for schizophrenia spectrum disorders by comparing 12 study design, demographical and clinical variables in different intervention categories: antipsychotics (AP), other pharmacological agents (OPA), brain stimulation (BS), psychological/psychosocial (PSI), lifestyle (LS), mixed interventions. Kruskal-Wallis and Chi-square tests measured differences between intervention-groups. Out of 19,935 articles, 489 (AP=149/OPA=187/BS=49/PSI=79/LS=19/mixed=6) were selected for data extraction. Concerning study designs, AP had the largest average arm size (mean ± SD=91.1 ± 122.8participants), OPA the highest double/triple-blinding (97.9 %) rates, PSI the longest follow-up (26.7 ± 21.8weeks). Age/gender demographical differences were significant but of negligible magnitude. OPA illness duration (14.8 ± 9.0years) was longer compared to AP (11.4 ± 6.7years). Positive and Negative Syndrome Scale (PANSS) negative scores were milder in PSI (18.6 ± 6.9) compared to AP/OPA/BS (23.8 ± 6.4/23.4 ± 4.9/24.2 ± 9.2). PANSS total scores were worse in AP (83.6 ± 18.2) than in OPA/BS/PSI (77.1 ± 20.5/75.5 ± 14.7/67.0 ± 23.3). The same was true for dropout rates (AP=25.5 %, OPA/BS/PSI=14.3/9.7/14.5 %). Prevalent treatment as usual was “none” for AP (36.7 %) and “antipsychotic” for other categories (42.3–82.8 %). Implementing cross-over, factorial or multi-arm designs may increase the comparability between studies investigating different intervention categories. Concerning clinical differences, reporting individual treatments at baseline and clinical severity, evaluating cognitive profiles and considering patients’ perspectives will allow to better understand the efficacy of the available treatments and develop tailored interventions.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"347 ","pages":"Article 116406"},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex and youth mental health during the COVID-19 pandemic","authors":"Nathalie Auger ,&nbsp;Gabriel Côté-Corriveau ,&nbsp;Aimina Ayoub ,&nbsp;Mimi Israël ,&nbsp;Howard Steiger ,&nbsp;Nicholas Chadi ,&nbsp;Nancy Low","doi":"10.1016/j.psychres.2025.116403","DOIUrl":"10.1016/j.psychres.2025.116403","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116403"},"PeriodicalIF":4.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal cannabis use disorder and offspring behavioral outcomes: findings from a linked data cohort study","authors":"Abay Woday Tadesse ,&nbsp;Berihun Assefa Dachew ,&nbsp;Getinet Ayano ,&nbsp;Kim Betts ,&nbsp;Rosa Alati","doi":"10.1016/j.psychres.2025.116404","DOIUrl":"10.1016/j.psychres.2025.116404","url":null,"abstract":"<div><div>Few studies have explored the association between maternal gestational cannabis use and disruptive behavioural disorders (DBDs) in offspring, often relying on self-reported data and small samples. This study aimed to assess the relationship between maternal cannabis use disorder (CUD) during pregnancy and postpartum periods and the risk of disruptive behaviours in offspring. We conducted a population-based retrospective cohort study using linked health data from New South Wales, Australia, for live births between 2003 and 2005. Mothers with CUD were compared to those without, and the risk of DBDs in offspring was estimated. Both CUD and disruptive behavioural disorders were identified using the International Classification of Disease (ICD) codes. Generalised Linear Models (GLMs) with log-binomial regression were fitted to estimate disruptive behavioural disorder risk in children. Statistical significance was set at <em>p &lt;</em> 0.05.</div><div>After adjusting for key confounders, this study revealed significantly higher risks of disruptive behavioural disorders in children of mothers with CUD during the antenatal [risk ratio (RR) = 3.56, 95 % CI 2.42–5.05], perinatal [RR = 3.55, 95 % CI 2.45–4.98], and postnatal [RR = 2.95, 95 % CI 1.23–6.16] periods compared to non-exposed counterparts. These findings underscore the importance of preconception, antenatal, and postnatal counselling on maternal cannabis use to mitigate neurobehavioral risks in children.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116404"},"PeriodicalIF":4.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of narcolepsy in representative samples of the general population of North America, Europe, and South Korea","authors":"Maurice M. Ohayon ,&nbsp;Shreya Dave ,&nbsp;Stephen Crawford ,&nbsp;Todd J Swick ,&nbsp;Marie-Lise Côté","doi":"10.1016/j.psychres.2025.116390","DOIUrl":"10.1016/j.psychres.2025.116390","url":null,"abstract":"<div><h3>Objectives</h3><div>Narcolepsy is a rare, chronic, central disorder of hypersomnolence characterized by excessive daytime sleepiness, hypnagogic/hypnopompic hallucinations, sleep paralysis, disrupted nighttime sleep, and sometimes cataplexy (Type 1). The objective of this study was to assess the prevalence of narcolepsy in a large representative general population sample in North America, Europe, and Asia.</div></div><div><h3>Methods</h3><div>This cross-sectional epidemiological study utilized data from the Sleep-EVAL research database. The study involved 61,754 participants from 10 countries interviewed between 1992 and 2016 using the Sleep-EVAL Expert System, an artificial intelligence system designed to conduct interviews and perform positive and differential diagnoses based on interview responses. Using the answers provided for each symptom, the expert system built its diagnostic tree to reach a diagnostic conclusion of narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) for each participant according to the <em>International Classification of Sleep Disorders</em>, Third Edition, criteria.</div></div><div><h3>Results</h3><div>Overall, the prevalence of NT1 was estimated to be 19.1/100,000 persons and the prevalence of NT2 was 23.3/100,000 persons. Prevalence of NT1 and NT2 was similar between countries and between men and women. Highest prevalence was among participants aged 35 years or younger for NT1 and among participants aged 35−54 years for NT2.</div></div><div><h3>Conclusions</h3><div>Our study, based on data from the general populations of several countries, shows that narcolepsy is a rare disorder, affecting 42.4/100,000 persons.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"347 ","pages":"Article 116390"},"PeriodicalIF":4.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suicide after psychedelic-assisted treatment in context","authors":"M. Earleywine ,&nbsp;Zachary Herrmann ,&nbsp;Sarah Slabaugh","doi":"10.1016/j.psychres.2025.116399","DOIUrl":"10.1016/j.psychres.2025.116399","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116399"},"PeriodicalIF":4.2,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143438023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of alpha neurofeedback training to enhance sleep in remitted depression and anxiety sufferers with persistent insomnia","authors":"Tsung-Hua Lu ,&nbsp;Tsung-Hao Hsieh ,&nbsp;Yung-Hung Wang ,&nbsp;Fu-Zen Shaw ,&nbsp;Po See Chen ,&nbsp;Sheng-Fu Liang","doi":"10.1016/j.psychres.2025.116401","DOIUrl":"10.1016/j.psychres.2025.116401","url":null,"abstract":"<div><div>This study evaluates whether neurofeedback training (NFT) to boost alpha wave activity in the central brain may effectively mitigate persistent insomnia in patients with remitted depression and anxiety. Thirty-two participants in clinical remission from depression or anxiety were enrolled and evaluated for insomnia severity. Individuals were randomly assigned in a single-blinded manner to either NFT or the sham treatment. The effectiveness of the intervention was measured using recognized scales for depression, anxiety and sleep quality. While subjective sleep quality, measured by the PSQI, showed significant improvements in the active group compared to the sham group at post training, 1-month, 3-month, and 6-month follow-up, objective measures of sleep quality largely remained within the normal range, with few significant changes observed. Specifically, the active group exhibited notable improvements in alpha amplitude and duration during NFT sessions, which were not seen in the sham group. This highlights the potential of NFT as a complementary approach for improving sleep perception in this population, but further research is needed to confirm its effects on actual sleep architecture and long-term outcomes.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116401"},"PeriodicalIF":4.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) – The PREVAIL study","authors":"Spyros Papapetropoulos ,&nbsp;Elizabeth Doolin ,&nbsp;Michael Odontiadis ,&nbsp;Dharam Paul ,&nbsp;Mark Jaros ,&nbsp;Paul Rolan ,&nbsp;Charles Taylor ,&nbsp;Murray B. Stein","doi":"10.1016/j.psychres.2025.116387","DOIUrl":"10.1016/j.psychres.2025.116387","url":null,"abstract":"<div><div>Social anxiety disorder (SAD) is a chronic, debilitating, and prevalent neuropsychiatric condition for which an acute, as-needed therapy is an unmet medical need. This Phase 2 study evaluated a potential novel, fast-acting, anxiolytic, BNC210, in SAD patients (NCT05193409). PREVAIL was a placebo-controlled, acute dose study of 225 mg and 675 mg BNC210 in 151 adult participants with SAD. Anxiety was evaluated by self-report efficacy scales during the anticipation and performance phases of a simulated public speaking challenge. Safety data were collected. Least squares mean ± standard error (SE) differences compared to placebo for the Subjective Units of Distress Scale (SUDS) scores for the change from baseline to the average of the performance phase were -6.6 ± 4.75 for 225 mg BNC210 and -4.8 ± 4.73 for 675 mg BNC210 (not significant). A <em>post hoc</em> analysis of SUDS scores evaluating combined BNC210 doses and speaking challenge phases (anticipation and performance) revealed a nominally statistically significant reduction compared to placebo (<em>p</em> = 0.044; effect size 0.36). Both dose levels of BNC210 demonstrated a favorable safety profile. PREVAIL supported further testing of 225 mg BNC210 as a potential safe and effective anxiolytic for acute, as-needed treatment of SAD. A Phase 3 trial is ongoing.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116387"},"PeriodicalIF":4.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent variable analysis of adherence to antipsychotics among south carolina medicaid beneficiaries with schizophrenia or schizoaffective disorder","authors":"Chao Cai ,&nbsp;Pujing Zhao ,&nbsp;Charmi Patel ,&nbsp;Carmela Benson ,&nbsp;Ismaeel Yunusa ,&nbsp;Chris Kozma ,&nbsp;Gene Reeder","doi":"10.1016/j.psychres.2025.116402","DOIUrl":"10.1016/j.psychres.2025.116402","url":null,"abstract":"<div><div>Schizophrenia and schizoaffective disorder are chronic mental illnesses that may lead to positive symptoms, negative symptoms, or cognitive symptoms. This study examined latent classes within medication adherence profiles for long-acting injectable antipsychotics (LAIs) and oral antipsychotics (OAPs). Latent profile analysis (LPA) and multinomial logistic regression models were used to explore the association between patient characteristics and latent class membership. Four latent classes were identified using LPA with observed adherence measures. The classes were labeled as “best adherent”, “intermittent adherent”, “early drop-off”, and “worst adherent”, with their respective estimated prevalences of 58 %, 17 %, 9 %, and 16 %. Multinomial logistic regression showed that patients on LAIs were more likely to belong to the “best adherent” group than to the non-adherent groups (“intermittent adherent”, “early drop-off”, and “worst adherent”) when compared to those on OAPs. These findings may contribute to the development of strategies for medication prescription and disease management for people with schizophrenia or schizoaffective disorder.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116402"},"PeriodicalIF":4.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota causes depressive phenotype by modulating glycerophospholipid and sphingolipid metabolism via the gut-brain axis","authors":"Yanan Cao ,&nbsp;Xiaoxiao Fan ,&nbsp;Tianzi Zang ,&nbsp;Yanting Li ,&nbsp;Yiming Tu ,&nbsp;Yi Wei ,&nbsp;Jinbing Bai ,&nbsp;Yanqun Liu","doi":"10.1016/j.psychres.2025.116392","DOIUrl":"10.1016/j.psychres.2025.116392","url":null,"abstract":"<div><div>Emerging evidence suggests that changes in the gut microbiota (GM) are related to prenatal depression onset, but the underlying molecular mechanisms remain obscure. This study was conducted to explore how disordered GM is involved in the onset of prenatal depression through the microbiome-gut-brain (MGB) axis. We transplanted fecal microbiota from women with and without prenatal depression into germ-free mice. Fecal metagenomic sequencing and LC-MS untargeted metabolomics analysis were performed to identify the GM composition, function, and metabolites in mice. Lipid metabolomics analysis was then used to characterize the lipid metabolism of brain tissue in mice. We found that mice transplanted with fecal microbiota from women with prenatal depression exhibited depressive-like behaviors as well as characteristic disorders of the phylum <em>Firmicutes</em>. Weighted Gene Correlation Network Analysis identified three microbial and one metabolic module in the gut, alongside two lipid metabolic modules in the brain, as significantly related to all depressive-like behaviors. These modules were enriched for glycerophospholipid and sphingolipid metabolism. In addition, the GM of mice with depressive-like behaviors were enriched and deficient in relevant functions and enzymes in the glycerophospholipid (mainly phosphatidylethanolamine) and sphingolipid (mainly hexosyl-ceramide) metabolic pathways, respectively. Consistently, glycerophospholipid and sphingolipid metabolites in the brains of depressive-like mice were up- and down-regulated. Increased phosphatidylethanolamine and decreased hexosyl-ceramide were significantly related to differential genera in the gut. Collectively, our findings provide a novel microbial and metabolic framework for understanding the role of the MGB axis in prenatal depression, indicating that the GM may be involved in the onset of depressive phenotypes by modulating central glycerophospholipid and sphingolipid metabolic homeostasis.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116392"},"PeriodicalIF":4.2,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}